Have a burning question on venture capital you need answered? Join OUP for our first ever ‘Ask a VC’ webinar, a session where our partner TTOs can ask Managing Partners Marc Singer and Bill Harrington anything and everything as it pertains to venture capital operations, decision-making, and the current investing environment.
Osage University Partners’ (OUP) Manager Partner Bill Harrington walks through various cap table scenarios of a hypothetical biotech university startup company called ‘Biostar Biotech.’
Bill highlights three different possible financial outcomes for this company’s investors and equity stakeholders, including a successful exit, a down round, and a company failure. A payout waterfall will be analyzed for each scenario, ending with a side-by-side returns comparison.
Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?
A lively discussion about the changing investment and development opportunities for early stage startups in the medical device sector. Osage University Partners briefly reviews investment activity from the past 15 years, followed by a conversation and Q&A with Mike Carusi of Lightstone Ventures and Hanson Gifford from The Foundry. Mike and Hanson have been active in the medtech space for many years and between them amount some of the largest exits the sector has seen. Our panelists cover current areas of investment interest, provide an informed analysis of global medical device market dynamics and trends, and offer their suggestions on how to advance university-originated medical device concepts, inventions, and companies.